Vivos Therapeutics (VVOS) Cash & Equivalents (2019 - 2026)

Vivos Therapeutics (VVOS) has reported Cash & Equivalents for 8 consecutive years, with $2.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 8.26% year-over-year to $2.1 million; the TTM figure through Mar 2026 stood at $2.1 million (down 8.26% YoY), while the FY2025 annual figure was $2.0 million, down 67.59% from the prior year.
• Cash & Equivalents rose to $2.1 million in Q1 2026 per VVOS's latest filing, from $2.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $17.8 million in Q1 2022 and bottomed at $988000.0 in Q3 2023.
• Historically, Cash & Equivalents has averaged $5.3 million across 5 years, with a median of $3.9 million in 2023.
• Annual changes were most pronounced in 2022 — Cash & Equivalents sank 85.34% — and 2024, when it jumped 537.65%.
• Vivos Therapeutics' Cash & Equivalents stood at $3.5 million in 2022, then slumped by 53.31% to $1.6 million in 2023, then soared by 281.01% to $6.3 million in 2024, then tumbled by 67.59% to $2.0 million in 2025, then grew by 3.99% to $2.1 million in 2026.
• Business Quant data shows VVOS's Cash & Equivalents at $2.1 million in Q1 2026, $2.0 million in Q4 2025, and $3.1 million in Q3 2025.